Moran, C;
Habeb, AM;
Kahaly, GJ;
Kampmann, C;
Hughes, M;
Marek, J;
Rajanayagam, O;
... Chatterjee, K; + view all
(2017)
Homozygous Resistance to Thyroid Hormone β: Can Combined Antithyroid Drug and Triiodothyroacetic Acid Treatment Prevent Cardiac Failure?
Journal of the Endocrine Society
, 1
(9)
pp. 1203-1212.
10.1210/js.2017-00204.
Preview |
Text (Published article)
JES Homozygous Case 2017 FINAL.pdf - Accepted Version Download (894kB) | Preview |
Preview |
Text (Supplementary data)
Moran_Homozygous_Resistance_Thyroid_Hormone_Suppl.pdf Download (118kB) | Preview |
Preview |
Text (Supplementary figure 1)
Moran_Homozygous_Resistance_Thyroid_Hormone_Fig1.pdf Download (78kB) | Preview |
Preview |
Text (Supplementary figure 2)
Moran_Homozygous_Resistance_Thyroid_Hormone_Fig2.pdf Download (227kB) | Preview |
Preview |
Text (Supplementary figure 3)
Moran_Homozygous_Resistance_Thyroid_Hormone_Fig3.pdf Download (44kB) | Preview |
Abstract
Resistance to thyroid hormone β (RTHβ) due to homozygous THRB defects is exceptionally rare, with only five kindreds reported worldwide. Cardiac dysfunction, which can be life-threatening, is recognized in the disorder. Here we describe the clinical, metabolic, ophthalmic, and cardiac findings in a 9-year-old boy harboring a biallelic THRB mutation (R243Q), along with biochemical, physiologic, and cardiac responses to carbimazole and triiodothyroacetic acid (TRIAC) therapy. The patient exhibits recognized features (goiter, nonsuppressed thyroid-stimulating hormone levels, upper respiratory tract infections, hyperactivity, low body mass index) of heterozygous RTHβ, with additional characteristics (dysmorphic facies, winging of scapulae) and more markedly elevated thyroid hormone levels, associated with the homozygous form of the disorder. Notably, an older sibling with similar clinical features and probable homozygous RTHβ had died of cardiac failure at age 13 years. Features of early dilated cardiomyopathy in our patient prompted combination treatment with carbimazole and TRIAC. Careful titration of therapy limited elevation in TSH levels and associated increase in thyroid volume. Subsequently, sustained reduction in thyroid hormones with normal TSH levels was reflected in lower basal metabolic rate, gain of lean body mass, and improved growth and cardiac function. A combination of antithyroid drug and TRIAC therapy may prevent thyrotoxic cardiomyopathy and its decompensation in homozygous or even heterozygous RTHβ in which life-threatening hyperthyroid features predominate.
Archive Staff Only
 |
View Item |
